Biotechnology News ORENCIA Search

| Biotechnology feed | All feeds

BioNews
Biotechnology, Pharmaceutical and Life Science News

Search Results

Documents 1-8 out of 8 found

Current Search: orencia: 8

Commercial Insight: Rheumatoid arthritis - Anti-TNFs defend first-line biologic position despite competition
Datamonitor forecasts that total sales for the seven major rheumatoid arthritis markets will grow from $7 billion in 2007 to over $12 billion in 2017.

The sustained uptake of anti-TNFs combined with the launch of several new biologic...

Datamonitor: Dec 24 2008 5:35AM
Matching: orencia

Find similar documents

Citi Upgrades Bristol-Myers Squibb (BMY) to Buy
Citi upgrades Bristol-Myers Squibb (NYSE: BMY) from Hold to Buy.

Citi analyst says, 'We project three-year incremental pharmaceutical revenue of ~$3.4 billion in 2011.

The largest contributors to incremental revenues are core in-line...

Street Insider: Dec 10 2008 2:22PM
Matching: orencia

Find similar documents

Ontario funds diabetes, cancer drugs
The Ontario government yesterday announced funding for new drugs to treat diabetes and colorectal cancer.

The drugs include Lantus, an extended, long-acting insulin; and Vectibix, a new intravenous drug used for colorectal cancer patients...

National Post: Dec 4 2008 2:30PM
Matching: orencia

Find similar documents

Data Demonstrate ORENCIA(R) (abatacept) Improves Health-Related Quality of Life, Pain and Sleep Quality in Chi
Company Website: http://www.bms.com SAN FRANCISCO -- (Business Wire) Bristol-Myers Squibb Company (NYSE: BMY) today announced at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco results from a 10-month...

Stockwatch: Oct 28 2008 12:46AM
Matching: orencia

Find similar documents

Data Demonstrate ORENCIA(R) (abatacept) Improves Health-Related Quality of Life, Pain and Sleep Quality in Chi
SAN FRANCISCO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY - News) today announced at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco results from a 10-month study which showed that ...

Business Wire via Yahoo!: Oct 28 2008 12:42AM
Matching: orencia

Find similar documents

BRIEF-Bristol-Myers Study results
Oct 27 (Reuters) - Oct 27 (Reuters) - Bristol-Myers Squibb Co: * Study results demonstrate more patients with early erosive rheumatoid arthritis treated with Orencia(R) (abatacept) and methotrexate (mtx) achieved das28 (crp)-defined...

Sharewatch: Oct 28 2008 5:58AM
Matching: orencia

Find similar documents

Study Results Demonstrate More Patients With Early Erosive Rheumatoid Arthritis Treated With ORENCIA(R) (abata
Phase III Study Also Demonstrated Less Radiographic Progression With ORENCIA and MTX in These PatientsCompany Website: http:www.bms.comSAN FRANCISCO -- (Business Wire) (NYSE: BMY) today announced results from a Phase IIIb study in...

Stockwatch: Oct 27 2008 11:03PM
Matching: orencia

Find similar documents

ZymoGenetics gets $21 million to end patent suit
ZymoGenetics will receive $21 million to settle a patent infringement lawsuit against Bristol-Myers Squibb, the company said in a regulatory filing Thursday.

The Seattle-based biotech sued in August 2006 over the pharmaceutical giant's...

Seattle Times: Oct 23 2008 6:20PM
Matching: orencia

Find similar documents

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.